Direct Oral Anticoagulants (DOACs) Device Market Forecast 2026–2035: Data Trends and Industry Insights
Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
How much is the Direct Oral Anticoagulants (DOACs) Device Market valued at in 2026, and what valuation is forecast for 2030?
The direct oral anticoagulants (doacs) device market has demonstrated substantial growth in recent years. This market is projected to expand from $32.8 billion in 2025 to $35.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The growth observed in the past can be attributed to aspects such as the limited availability of doac monitoring devices, a reliance on hospital-based coagulation tests, the growing prevalence of atrial fibrillation and thrombotic disorders, the adoption of oral anticoagulant therapies, and an increasing demand for patient safety and anticoagulation monitoring.
The direct oral anticoagulants (doacs) device market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $49.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. Factors driving this growth during the forecast period include technological improvements in portable and point-of-care devices, the incorporation of digital health platforms alongside cloud-based monitoring, increasing acceptance of personalized anticoagulation management, the expansion of homecare and specialized clinic services, and a rise in regulatory approvals for new monitoring systems. Key trends emerging over the forecast horizon encompass a greater uptake of point-of-care doac monitoring devices, an expanding utilization of factor xa and direct thrombin inhibitor monitoring, heightened awareness regarding stroke and thromboembolism prevention, the broadening of homecare and ambulatory monitoring solutions, and an intensified emphasis on precision, sensitivity, and swift testing capabilities.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp
What Drivers Are Influencing The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?
The growing occurrence of cardiovascular conditions is projected to boost the expansion of the direct oral anticoagulants (DOACs) device market in the future. These conditions encompass various ailments affecting the heart and blood vessels, frequently resulting in problems such as heart attacks, strokes, or other circulatory issues. The increase in cardiovascular disorders is linked to more sedentary ways of life, which contribute to weight gain, higher blood pressure, and a gradual weakening of cardiovascular function. Direct oral anticoagulants (DOACs) aid in addressing cardiovascular disorders by efficiently reducing the risk of stroke and blood clots for individuals with atrial fibrillation, providing dependable anticoagulation without requiring regular blood tests. As an illustration, in October 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, cardiovascular disease was responsible for 919,032 lives, making up one in every three deaths. Coronary heart disease continued to be the most common type of heart disease, and significantly, roughly one in six deaths attributed to cardiovascular diseases affected adults under 65 years. Consequently, the rising incidence of cardiovascular disorders is fueling the growth of the direct oral anticoagulants (DOACs) device market.
What Segments Are Included Within The Direct Oral Anticoagulants (DOACs) Device Market?
The direct oral anticoagulants (doacs) device market covered in this report is segmented –
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate
How Are New Market Trends Shaping The Landscape Of The Direct Oral Anticoagulants (DOACs) Device Market?
Leading companies in the direct oral anticoagulants (DOACs) device market are concentrating on developing advanced solutions, such as automated coagulation assays, to improve the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. These automated coagulation assays are machine-operated laboratory tests that measure the speed at which blood clots, aiding in the diagnosis of bleeding or clotting disorders. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically designed for Factor Xa inhibitors. These tests enhance clinicians’ ability to accurately evaluate the anticoagulation status of patients taking direct Factor Xa inhibitors such as rivaroxaban and apixaban. They further assist clinical decision-making by precisely measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios like bleeding, overdose, or urgent surgery. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated tests deliver high-quality results, minimize manual handling, and streamline laboratory workflow efficiency.
Who Are The Core Companies Influencing Trends In The Direct Oral Anticoagulants (DOACs) Device Market?
Major companies operating in the direct oral anticoagulants (doacs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., DOASENSE GmbH.
Access The Complete Report For Deeper Market Insights:
Which Geographic Areas Are Emerging As Strong Markets For The Direct Oral Anticoagulants (DOACs) Device Market?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2025. The regions covered in the direct oral anticoagulants (doacs) device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Direct Oral Anticoagulants (DOACs) Device Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp
Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2026, By The Business Research Company
Machine Learning Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report
Financial Analytics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report
Machine Learning Ml In The Pharmaceutical Industry Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
